Scientists identified two main hormones responsible: Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide (GLP-1)
Lukey MJ, Greene KS, Erickson JW, Wilson KF, Cerione RA
Specifically, people with a personal or family history of thyroid cancer, including medullary thyroid carcinoma (MTC), should not use semaglutide GLP-1 due to an increased risk of developing thyroid tumors
We encourage our patients to openly discuss their preferences and lifestyle needs with us, as this greatly influences the choice of medication
Olson CE (1988)
Retatrutide metabolic benefits Retatrutide produces all of the metabolic benefits seen with Mounjaro plus additional improvements that appear unique to triple agonism: Blood sugar control: HbA1c reductions of 1.3% to 2.0% at doses of 4-12 mg in type 2 diabetes Blood pressure: Systolic blood pressure reduction of up to 14.0 mmHg at the highest dose (roughly double what Mounjaro achieves) Lipids: Non-HDL cholesterol and triglyceride reductions Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia Inflammatory markers: Significant reductions in high-sensitivity C-reactive protein But the standout metabolic benefit, the one that has researchers most excited, is the effect on liver health